dulaglutide vs tirzepatide Long-awaited SURPASS-CVOT: Cardiovascular Outcomes with in NEJM: #tirzepatide noninferior to #dulaglutide for 3-point MACE in T2D with ASCVD, with greater improvements in weight, A1c, BP, triglycerides, and kidney function What is the preferred treatment
Pay in 4 interest-free payments of $6.12 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Sep 3 - Sep 8


:max_bytes(150000):strip_icc():focal(745x452:747x454)/zepbound-weightloss-110923-tout-efdb9ac95d0440a9b11ad06820bf37d2.jpg)




















